Northern Trust Corp increased its holdings in AtriCure Inc. (NASDAQ:ATRC) by 5.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 439,926 shares of the medical device company’s stock after purchasing an additional 24,696 shares during the period. Northern Trust Corp owned approximately 1.24% of AtriCure worth $11,899,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. increased its position in AtriCure by 105.1% in the first quarter. JPMorgan Chase & Co. now owns 14,208 shares of the medical device company’s stock worth $292,000 after purchasing an additional 7,281 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in AtriCure in the second quarter worth $301,000. BlueMountain Capital Management LLC increased its position in AtriCure by 121.8% in the second quarter. BlueMountain Capital Management LLC now owns 14,904 shares of the medical device company’s stock worth $403,000 after purchasing an additional 8,184 shares during the last quarter. GSA Capital Partners LLP increased its position in AtriCure by 135.4% in the second quarter. GSA Capital Partners LLP now owns 26,054 shares of the medical device company’s stock worth $705,000 after purchasing an additional 14,984 shares during the last quarter. Finally, Rhumbline Advisers increased its position in AtriCure by 9.5% in the second quarter. Rhumbline Advisers now owns 32,455 shares of the medical device company’s stock worth $878,000 after purchasing an additional 2,807 shares during the last quarter. Institutional investors own 86.81% of the company’s stock.
NASDAQ ATRC opened at $33.65 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.62 and a debt-to-equity ratio of 0.31. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -40.54 and a beta of 0.16. AtriCure Inc. has a 52 week low of $14.88 and a 52 week high of $36.49.
Several equities research analysts recently weighed in on ATRC shares. Zacks Investment Research upgraded shares of AtriCure from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a research report on Tuesday. BTIG Research reaffirmed a “hold” rating on shares of AtriCure in a research note on Thursday, August 2nd. Needham & Company LLC lifted their price objective on shares of AtriCure from $36.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, October 4th. Stifel Nicolaus lifted their price objective on shares of AtriCure from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $37.00 price objective on shares of AtriCure in a research note on Thursday, August 2nd. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. AtriCure has a consensus rating of “Buy” and a consensus target price of $35.80.
In other AtriCure news, SVP Justin J. Noznesky sold 4,000 shares of AtriCure stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $30.32, for a total transaction of $121,280.00. Following the completion of the transaction, the senior vice president now directly owns 124,920 shares of the company’s stock, valued at $3,787,574.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This story was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.wkrb13.com/2018/11/09/northern-trust-corp-increases-position-in-atricure-inc-atrc.html.
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
See Also: Fundamental Analysis
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.